Rehabilitation to improve gaze and postural stability in people with multiple sclerosis: study protocol for a prospective randomized clinical trial.

Rehabilitation to improve gaze and postural stability in people with multiple sclerosis: study protocol for a prospective randomized clinical trial.

Publication date: Jun 10, 2019

The use of vestibular rehabilitation principles in the management of gaze and postural stability impairments in people with multiple sclerosis (PwMS) has shown promise in pilot work completed in our lab and in a recently published randomized clinical trial (RCT). However, further work is needed to fully quantify the gaze and postural impairments present in people with multiple sclerosis and how they respond to rehabilitation.

The study is a single blind RCT designed to examine the benefit of a gaze and postural stability (GPS) intervention program compared to a standard of care (SOC) rehabilitation program in dizzy and balance impaired PwMS. Outcomes will be collected across the domains of body structure and function, activity, and participation as classified by the World Health Organization International Classification of Functioning, Disability, and Health (ICF). Our primary outcomes are the Dizziness Handicap Inventory (DHI) and the Functional Gait Assessment (FGA). Secondary outcomes include other measures of gaze and postural stability, fatigue, and functional mobility. Participants who are interested and eligible for enrollment will be consented prior to completing a baseline assessment. Following the baseline assessment each participant will be randomized to either the GPS or SOC intervention group and will complete a 6 week treatment period. During the treatment period, both groups will participate in guided exercise 3x/week. Following the treatment period participants will be asked to return for a post-treatment evaluation and again for a follow-up assessment 1 month later. We anticipate enrolling 50 participants.

This study will be an innovative RCT that will utilize gaze and postural stability metrics to assess the efficacy of vestibular rehabilitation in PwMS. It will build on previous work by examining measures across the ICF and improve the current evidence base for treating PwMS.

ClinicalTrials.gov, May 29th 2018, NCT03521557 .

Open Access PDF

Loyd, B.J., Fangman, A., Peterson, D.S., Gappmaier, E., Schubert, M.C., Thackery, A., and Dibble, L. Rehabilitation to improve gaze and postural stability in people with multiple sclerosis: study protocol for a prospective randomized clinical trial. 18281. 2019 BMC Neurol (19):1.

Concepts Keywords
BMC GPS
Dizziness Dizziness
Fatigue Sclerosis protocol
GPS Clinical trial
Multiple Sclerosis Randomized controlled trial
Protocol Vestibular rehabilitation
Randomized Clinical Trial Biomechanics
Single Blind Physical fitness
Vestibular Balance
Neurological disorders
Design of experiments
Clinical research
Health
Articles
Stability fatigue
Present multiple sclerosis

Semantics

Type Source Name
gene UNIPROT SOAT1
gene UNIPROT COL4A5
gene UNIPROT SLC2A10
disease DOID ATS
disease DOID ATS
gene UNIPROT NR5A2
drug DRUGBANK Silver
gene UNIPROT INTU
gene UNIPROT TNIP1
gene UNIPROT RHNO1
pathway BSID Aging
disease MESH aging
disease DOID Vestibular neuritis
disease MESH Vestibular neuritis
gene UNIPROT MBNL1
disease DOID cerebral palsy
disease MESH cerebral palsy
disease MESH Mult
gene UNIPROT COL9A3
gene UNIPROT COMP
gene UNIPROT COL9A1
gene UNIPROT COL9A2
gene UNIPROT SCN8A
gene UNIPROT ZBTB8OS
disease MESH development
gene UNIPROT TNFSF13
gene UNIPROT ANP32B
gene UNIPROT SMIM10L2A
gene UNIPROT SMIM10L2B
disease DOID SPMS
disease DOID RRMS
disease MESH Primary progressive multiple sclerosis
disease MESH multiple
gene UNIPROT IRF1
gene UNIPROT DNMT1
gene UNIPROT CD69
gene UNIPROT CD5L
gene UNIPROT RNMT
gene UNIPROT MET
gene UNIPROT SLTM
drug DRUGBANK Methionine
gene UNIPROT RTRAF
gene UNIPROT EIF2B5
disease DOID cle
disease DOID cle
gene UNIPROT KCNJ5
gene UNIPROT CIR1
gene UNIPROT ANXA13
disease MESH vertigo
gene UNIPROT ABCB6
drug DRUGBANK Abacavir
disease DOID stroke
disease MESH stroke
gene UNIPROT ASPSCR1
drug DRUGBANK Gold
disease MESH sitting position
gene UNIPROT RIOX2
gene UNIPROT FANCE
gene UNIPROT ELOVL6
disease DOID face
disease MESH visual
drug DRUGBANK Coenzyme M
drug DRUGBANK Esomeprazole
gene UNIPROT FBN1
gene UNIPROT PTPN5
gene UNIPROT MEA1
drug DRUGBANK Cysteamine
gene UNIPROT FBLIM1
gene UNIPROT TRIM37
disease MESH diagnosis
gene UNIPROT SOD1
gene UNIPROT IGFALS
disease DOID als
gene UNIPROT PTPRF
gene UNIPROT ARMC9
gene UNIPROT AKR1A1
gene UNIPROT TBATA
disease MESH comorbidity
gene UNIPROT TRIM13
gene UNIPROT CXADR
gene UNIPROT CASR
gene UNIPROT NR1I3
gene UNIPROT SPG7
gene UNIPROT PRKAR1A
gene UNIPROT SERPINB6
gene UNIPROT SORBS1
gene UNIPROT BRD4
gene UNIPROT HACD1
gene UNIPROT LNPEP
gene UNIPROT CAP1
disease MESH community
gene UNIPROT DEPP1
gene UNIPROT GOPC
gene UNIPROT EFS
gene UNIPROT POLR3E
gene UNIPROT MENT
drug DRUGBANK Trestolone
gene UNIPROT SSRP1
gene UNIPROT LARGE1
disease DOID PPMS
gene UNIPROT SRMS
gene UNIPROT FANCC
disease MESH Sclerosis
gene UNIPROT INA
gene UNIPROT SLC35G1
disease MESH Gait
gene UNIPROT FGA
gene UNIPROT DNMT3B
drug DRUGBANK Isoxaflutole
gene UNIPROT UBXN11
gene UNIPROT NBEAL2
disease DOID GPS
gene UNIPROT LAT2
gene UNIPROT EGR3
disease MESH multiple sclerosis
disease DOID multiple sclerosis

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *